TVB-3664
Modify Date: 2024-01-13 17:52:44
TVB-3664 structure
|
Common Name | TVB-3664 | ||
|---|---|---|---|---|
| CAS Number | 2097262-58-1 | Molecular Weight | 468.47 | |
| Density | 1.36±0.1 g/cm3(Predicted) | Boiling Point | 665.7±55.0 °C(Predicted) | |
| Molecular Formula | C25H23F3N4O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of TVB-3664TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC50 values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression[1][2]. |
| Name | TVB-3664 |
|---|
| Description | TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC50 values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression[1][2]. |
|---|---|
| Related Catalog | |
| Target |
FASN[1][2]. |
| In Vitro | TVB-3664 (0-1 μM, 7 days) shows anti-tumor activity in CaCo2, HT29 and LIM2405 cell lines[1]. TVB-3664 decreases viability in multiple tumor cell lines from solid and hematopoietic tumor types[1]. Cell Proliferation Assay[1] Cell Line: CaCo2, HT29 and LIM2405 cell lines. Concentration: 0-1 μM. Incubation Time: 7 days. Result: Showed anti-tumor activity. |
| In Vivo | TVB-3664 (3 mg/kg (Pt 2614 and Pt 2449PT) or 6 mg/kg (Pt 2402 and Pt 2449LM), oral gavage, daily, 4 weeks) treatment leads to a significant reduction in tumor volume and tumor weight in Pt 2614, Pt 2449PT, and Pt 2402 PDX models, with an average reduction in tumor weight of 30%, 37.5% and 51.5%, respectively[1]. Animal Model: Colorectal cancer (CRC) PDX models in NOD-SCID-IL2rg-/- (NSG) mice using specimens collected from patients who had undergone surgery for resection of primary CRC or CRC metastasis[1]. Dosage: 3 mg/kg (Pt 2614 and Pt 2449PT) or 6 mg/kg (Pt 2402 and Pt 2449LM). Administration: Oral gavage daily for 4 weeks. Result: Led to a significant reduction in tumor volume and tumor weight in Pt 2614, Pt 2449PT, and Pt 2402 PDX models, with an average reduction in tumor weight of 30%, 37.5% and 51.5%, respectively. |
| References |
| Density | 1.36±0.1 g/cm3(Predicted) |
|---|---|
| Boiling Point | 665.7±55.0 °C(Predicted) |
| Molecular Formula | C25H23F3N4O2 |
| Molecular Weight | 468.47 |
| Storage condition | 2-8°C |